Presentation Title

Screening of Hybrid Heterocyclic Boronic Acids and Nonboronic Acid Aldehydes as Potential Anticancer Agents.

Presenter Status

Graduate Student, Biology Department

Presentation Type

Oral Presentation

Session

C

Location

Chan Shun 108

Start Date

19-5-2017 9:50 AM

End Date

19-5-2017 10:10 AM

Presentation Abstract

Breast cancer is one of the most frequently occurring cancers and the second leading cause of cancer-related deaths in women. Several risk factors and genetic mutations play a significant role in its occurrence as well as influence the development and implementation of anticancer therapy. This research is focused on the synthesis and anticancer evaluation of novel hybrid organic compounds containing the heterocycles rhodanine and 2, 4-thiazolidinedione covalently linked to boronic acids or nonboronic acid aldehydes. The synthesis of these compounds were accomplished by calcium oxide-promoted Knoevenagel condensation followed by NMR and IR spectroscopic analysis for structure confirmation. Eleven compounds were screened for anticancer effects on the AU565 HER-2/neu overexpressing breast cancer cell line by using the CellTiter-Blue® cell viability assay. Six of the compounds showed a decrease in cell viability which suggest anticancer activity while five of the compounds showed an increase in cell viability suggesting no anticancer activity. Overall, the results suggest that the position of the boronic acids and nonboronic acid aldehydes on the aromatic ring of the hybrid compounds may play a role in determining anticancer activity.

Biographical Sketch

Jemma McLeish

Graduate Student, Biology Department

Andrews University

This document is currently not available here.

Share

COinS
 
May 19th, 9:50 AM May 19th, 10:10 AM

Screening of Hybrid Heterocyclic Boronic Acids and Nonboronic Acid Aldehydes as Potential Anticancer Agents.

Chan Shun 108

Breast cancer is one of the most frequently occurring cancers and the second leading cause of cancer-related deaths in women. Several risk factors and genetic mutations play a significant role in its occurrence as well as influence the development and implementation of anticancer therapy. This research is focused on the synthesis and anticancer evaluation of novel hybrid organic compounds containing the heterocycles rhodanine and 2, 4-thiazolidinedione covalently linked to boronic acids or nonboronic acid aldehydes. The synthesis of these compounds were accomplished by calcium oxide-promoted Knoevenagel condensation followed by NMR and IR spectroscopic analysis for structure confirmation. Eleven compounds were screened for anticancer effects on the AU565 HER-2/neu overexpressing breast cancer cell line by using the CellTiter-Blue® cell viability assay. Six of the compounds showed a decrease in cell viability which suggest anticancer activity while five of the compounds showed an increase in cell viability suggesting no anticancer activity. Overall, the results suggest that the position of the boronic acids and nonboronic acid aldehydes on the aromatic ring of the hybrid compounds may play a role in determining anticancer activity.